500672 On Other Exchanges
Symbol
Exchange
500672 is not on other exchanges.

novartis india ltd (500672) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NOVARTIS INDIA LTD (500672)

Related News

No related news articles were found.

novartis india ltd (500672) Related Businessweek News

No Related Businessweek News Found

novartis india ltd (500672) Details

Novartis India Limited manufactures and sells healthcare products in India and internationally. It operates through four segments: Pharmaceuticals, Generics, Over-The-Counter, and Animal Health. The Pharmaceuticals segment offers a portfolio of prescription medicines through healthcare professionals. The Generics segment provides retail generics products in various therapeutic areas, such as anti-TB, anti-DUB (gynecology), anti-histamines, antibiotics, anti-ulcerants, anti-diabetes, and cardiovascular. The Over-The-Counter segment offers vitamins, minerals, and nutritional supplements, as well as products for the treatment of cough, cold, and allergy. The Animal Health segment provides products for the cattle and poultry markets. The company was founded in 1947 and is based in Mumbai, India. Novartis India Limited operates as a subsidiary of Novartis AG.

Founded in 1947

novartis india ltd (500672) Top Compensated Officers

Vice Chairman and Managing Director
Total Annual Compensation: 14.5M
Chief Financial Officer and Whole-Time Direct...
Total Annual Compensation: 12.0M
Executive Officer
Total Annual Compensation: --
Executive Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2016.
novartis india ltd
Novartis India Limited Recommends Dividend for the Financial Year Ended March 31, 2017

The Board of Directors of Novartis India Limited at its meeting held on May 23, 2017 recommended a dividend of INR 10 per share for the financial year ended March 31, 2017, subject to the approval of shareholders at the ensuing AGM. The Dividend, if approved by the shareholders, |will be paid within the prescribed statutory timelines.

Novartis India Limited Reports Standalone Unaudited Earnings Results for the Fourth Quarter and Audited Earnings Results for the Full Year Ended of March 31, 2017

Novartis India Limited reported standalone unaudited earnings results for the fourth quarter and audited earnings results for the full year ended of March 31, 2017. For the quarter, the company reported revenue from operations of INR 1,454.9 million compared to INR 1,662.1 million a year ago. Total income was INR 1,603.0 million against INR 1,871.9 million a year ago. Profit before tax from continuing operations was INR 71.6 million against INR 326.0 million a year ago. Profit from continuing operations was INR 29.1 million or INR 1.03 per basic and diluted share against INR 228.3 million or INR 7.14 per basic and diluted share a year ago. Profit for the period was INR 29.1 million or INR 1.03 per basic and diluted share against INR 228.3 million or INR 7.14 per basic and diluted share a year ago. For the year, the company reported revenue from operations of INR 6,562.3 million compared to INR 6,899.0 million a year ago. Total income was INR 7,263.8 million against INR 7,707.8 million a year ago. Profit before tax from continuing operations was INR 917.3 million against INR 1,113.7 million a year ago. Profit from continuing operations was INR 572.2 million or INR 19.10 per basic and diluted share against INR 724.9 million or INR 22.68 per basic and diluted share a year ago. Profit for the period was INR 572.2 million or INR 19.10 per basic and diluted share against INR 1,982.9 million or INR 62.04 per basic and diluted share a year ago.

Novartis India Limited, Board Meeting, May 23, 2017

Novartis India Limited, Board Meeting, May 23, 2017. Agenda: To consider audited results; and to consider final dividend.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

500672 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 500672.
View Industry Companies
 

Industry Analysis

500672

Industry Average

Valuation 500672 Industry Range
Price/Earnings 32.8x
Price/Sales 2.4x
Price/Book 1.9x
Price/Cash Flow 29.0x
TEV/Sales 1.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NOVARTIS INDIA LTD, please visit www.novartis.in. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.